The average P/S ratio for SNY's competitors is 4.59, providing a benchmark for relative valuation. Sanofi SA Corp (SNY) exhibits a P/S ratio of 2.45, which is -46.60% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.